GlassScriptPhysician profile
Saagar Jadeja
NPI 1952806515
$6,058.30
in general payments reported to CMS, 2019-2025
17 companies · $928 in 2025
The $928 reported for 2025 was more than what 87% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $108 · 2023: $3,688 · 2024: $1,335 · 2025: $928.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,957 · Consulting Fee: $2,800 · Education: $193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,957.31 |
| Consulting Fee | $2,800.00 |
| Education | $192.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $3,352.00 | 2022-2025 | Ilumya, Winlevi, Absorica Ld |
| Abbvie INC. | $538.89 | 2022-2025 | |
| Janssen Biotech, INC. | $519.66 | 2024-2025 | Tremfya, Stelara, Simponi Aria |
| Incyte Corporation | $348.93 | 2023-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $319.79 | 2023-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $253.45 | 2024-2025 | Taltz, Ebglyss, Olumiant |
| Ucb, INC. | $237.54 | 2024-2025 | Bimzelx |
| Genzyme Corporation | $151.39 | 2023-2024 | |
| Dermavant Sciences, INC. | $84.05 | 2023-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $63.57 | 2023 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $41.39 | 2024-2025 | |
| Organon LLC | $39.25 | 2025 | Vtama, Nexplanon |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.05 | 2022 | |
| Leo Pharma INC. | $22.76 | 2024 | Adbry |
| Galderma Laboratories, L.P. | $21.35 | 2025 | Nemluvio |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verrica Pharmaceuticals INC. | $18.31 | 2025 | Ycanth |
| Amgen INC. | $14.92 | 2025 | Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saagar Jadeja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.